Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
Circulating Cancer Associated Macrophage-like cells
biomarker
liquid biopsy
pancreatic ductal adenocarcinoma
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
17 Nov 2022
17 Nov 2022
Historique:
received:
01
09
2022
revised:
07
11
2022
accepted:
12
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Circulating Cancer Associated Macrophage-like cells (CAMLs) have been described as novel liquid biopsy analytes and unfavorable prognostic markers in some tumor entities, with scarce data for Pancreatic Ductal Adenocarcinomas (PDAC). Baseline and follow-up blood was drawn from resected curative ( CAMLs were detectable at baseline in 36.1% of resected patients and 47.4% of palliative PDAC patients. CAML detection was tumor stage independent. Follow-up data indicated that detection of CAMLs (in 45.5% of curative patients) was an independent prognostic factor for shorter recurrence-free survival (RFS) (HR: 4.3, This pilot study shows that detection of CAMLs in PDAC patients can provide prognostic information, either alone or even more pronounced in combination with CTCs, which indicates the power of liquid biopsy marker analyses.
Sections du résumé
BACKGROUND
BACKGROUND
Circulating Cancer Associated Macrophage-like cells (CAMLs) have been described as novel liquid biopsy analytes and unfavorable prognostic markers in some tumor entities, with scarce data for Pancreatic Ductal Adenocarcinomas (PDAC).
METHODS
METHODS
Baseline and follow-up blood was drawn from resected curative (
RESULTS
RESULTS
CAMLs were detectable at baseline in 36.1% of resected patients and 47.4% of palliative PDAC patients. CAML detection was tumor stage independent. Follow-up data indicated that detection of CAMLs (in 45.5% of curative patients) was an independent prognostic factor for shorter recurrence-free survival (RFS) (HR: 4.3,
CONCLUSIONS
CONCLUSIONS
This pilot study shows that detection of CAMLs in PDAC patients can provide prognostic information, either alone or even more pronounced in combination with CTCs, which indicates the power of liquid biopsy marker analyses.
Identifiants
pubmed: 36428523
pii: biomedicines10112955
doi: 10.3390/biomedicines10112955
pmc: PMC9687633
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Erich Und Gertrud Roggenbuck Stiftung
ID : 2072-100
Références
Cancers (Basel). 2019 Oct 26;11(11):
pubmed: 31717773
Biomedicines. 2022 Mar 02;10(3):
pubmed: 35327389
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34209696
PLoS One. 2017 Sep 28;12(9):e0184451
pubmed: 28957348
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3514-9
pubmed: 24550495
Cancers (Basel). 2022 Sep 10;14(18):
pubmed: 36139565
Front Cell Dev Biol. 2022 May 26;10:918795
pubmed: 35712663
Breast Cancer Res Treat. 2017 Oct;165(3):733-741
pubmed: 28687903
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424
pubmed: 30796368
Int J Mol Sci. 2022 Jan 31;23(3):
pubmed: 35163592
Oncotarget. 2017 Jul 18;8(47):82326-82343
pubmed: 29137267
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1037-42
pubmed: 27197300
Breast Cancer Res. 2014 Mar 06;16(2):R23
pubmed: 24602188
Clin Chem. 2021 Mar 31;67(4):631-641
pubmed: 33491069
Asian Pac J Cancer Prev. 2014;15(15):6015-20
pubmed: 25124566
Mol Oncol. 2016 Mar;10(3):374-94
pubmed: 26897752
PLoS One. 2015 Aug 12;10(8):e0134320
pubmed: 26267609
J Thorac Oncol. 2020 Sep;15(9):1460-1471
pubmed: 32416323
Cancers (Basel). 2019 Oct 26;11(11):
pubmed: 31717747
Tumour Biol. 2014 Mar;35(3):2473-80
pubmed: 24218336
Sci Adv. 2018 Sep 12;4(9):eaat7828
pubmed: 30214939
Cancers (Basel). 2020 Feb 13;12(2):
pubmed: 32069934
Cell Rep. 2022 Aug 30;40(9):111298
pubmed: 36044866
Clin Cancer Res. 2018 Jun 15;24(12):2844-2850
pubmed: 29559560